Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.53 |
| ▸ | MC4R | P32245 | 9/20 | 0.51 |
| ▸ | MC5R | P33032 | 9/20 | 0.51 |
| ▸ | MC3R | P41968 | 9/20 | 0.51 |
| ▸ | MC1R | Q01726 | 9/20 | 0.51 |
| ▸ | TSLP | Q969D9 | 7/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.49 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14274987 | 0.92 | CHRNA10 (0.55) | ITGB3ITGB1ITGAVITGA5MC4R | |
| SCHEMBL12146083 | 0.89 | TSLP (0.56) | MC4RMC5RMC3RMC1RTSLP | |
| SCHEMBL13074972 | 0.87 | CHRNA7 (0.46) | ITGB3ITGB1ITGAVITGA5MC4R | |
| SCHEMBL13038608 | 0.84 | MC4R (0.51) | ITGB3MC4RMC5RMC3RMC1R | |
| SCHEMBL13881404 | 0.84 | MC4R (0.51) | ITGB3MC4RMC5RMC3RMC1R | |
| SCHEMBL13038609 | 0.83 | CHRNA10 (0.55) | MC4RMC3RMC1RTSLPCTSG | |
| SCHEMBL10138562 | 0.80 | ITGB3 (0.59) | ITGB3ITGB1ITGAVITGA5MC4R | |
| SCHEMBL15397365 | 0.80 | ITGB3 (0.59) | ITGB3ITGB1ITGAVITGA5MC4R | |
| SCHEMBL12463308 | 0.79 | ITGB3 (0.57) | ITGB3ITGB1ITGAVITGA5MC4R | |
| SCHEMBL13319649 | 0.77 | CTSG (0.69) | TSLPPLAUCTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278932-A1 | POLYMER MICELLES CONTAINING SN-38 FOR THE TREATMENT OF CANCER | MUC1, MSN, SNX9 | ITGB3 2733/4885ITGB1 3151/4885ITGAV 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.